Abstract
Sotorasib, a novel, first-in-class, oral targeted therapy is in development for the treatment of KRAS p.G12C–mutated non-small cell lung cancer (NSCLC). The primary endpoint of sotorasib clinical studies reported to date has been objective response rate. Longer-term outcomes (e.g., overall survival) for sotorasib and patient preferences for treatment of KRAS p.G12C-mutated NSCLC are not currently available. Therefore, qualitative interviews were conducted with treatment-experienced patients with advanced KRAS p.G12C–mutated NSCLC to gain insight into: (a) patient experiences with treatment, (b) preferences for treatment attributes and benefit-risk profiles, and (c) willingness to accept uncertainty in longer-term treatment efficacy for a less toxic oral therapy in the second-line setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
